0 Vote
1 Contributor
70 Views
0 Saved
You might also be interested in
The risk is so low that it is impossible to read using tables of published health data and statistics. Children do get cancer, but very rarely breast cancer. Statistics will often group women aged 15–39 as “young women” but this is very misleading as the bump in cases begins in women over 20, or eve....
First of all, breast cancer isn't a death sentence: overall, about 60% of women survive breast cancer, and go on to live long and healthy lives. The percentage can be as high as 99%, depending on the particular type and stage of breast cancer. Stage 1, 2, 3 is easily curable by surgery followed b....
Although some information came out over the past five years that wearing a bra can be linked with increased cancer risk, there is zero scientific evidence that this is true. Bras were created to help women’s chests feel more supported, no matter the activity, and to decrease any discomfort or back p....
Receive guidance from the first consultation through the entire hospitalization process.
Medical experts assist the patients to find the right doctor and book appointments.
Consult with 5000+ doctors online and get all your health queries answered.
Rahul Sharma
Yes, PARP inhibitors are relatively newer class of drugs and scientists have just begun to explore their functionality and usage in Cancer treatment. LYNPARZA is the first and only PARP inhibitor approved in 2 distinct settings: For the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. For the treatment of adult patients with suspected deleterious germline BRCA-mutated advanced ovarian cancer which has been treated with 3 or more prior lines of chemotherapy. Patients should be selected for therapy based on an FDA-approved companion diagnostic for LYNPARZA. Poly (ADP-ribose) Polymerase, or PARP, enzymes mediate DNA repair by transferring ADP-ribose units to preexisting ADP-ribose chains on proteins and to proteins. This ADP–ribosylation process recruits DNA repair enzymes, thereby maintaining genomic integrity. Inhibiting this process can lead to the accumulation of DNA damage and, ultimately, cell death.